{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T22:49:30Z","timestamp":1780440570142,"version":"3.54.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T00:00:00Z","timestamp":1613952000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T00:00:00Z","timestamp":1613952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Information about health care use and costs of cutaneous T-cell lymphoma (CTCL) patients is limited, particularly in a European setting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this population-wide study we set out to investigate prevalence, and trends in health care use in two CTCL subtypes, mycosis fungoides (MF) and S\u00e9zary syndrome (SS) over a time period of 19\u2009years in 1998\u20132016 by using a nation-wide patient register containing data on all diagnosed MF and SS cases in Finland.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The prevalence of diagnosed MF and SS rose from 2.04 to 5.38\/100000, and from 0.16 to 0.36\/100000 for MF and SS respectively during 1998\u20132016. We found a substantial decrease in inpatient treatment of MF\/SS in the past two decades with a mean of 2 inpatient days\/patient\/year due to MF\/SS in 2016, while the mean numbers of MF\/SS related outpatient visits remained stable at 8 visits\/year\/patient. Most MF\/SS-related outpatient visits occurred in the medical specialty of dermatology. In a ten-year follow-up after MF\/SS diagnosis, the main causes for outpatient visits and inpatient stays were MF\/SS itself, other cancers, and other skin conditions. Also cardiovascular disease and infections contributed to the number of inpatient days. Mean total hospital costs decreased from 11,600 eur\/patient\/year to 3600 eur\/patient\/year by year 4 of the follow-up, and remained at that level for the remainder of the 10-year follow-up. MF\/SS accounted for approximately half of the hospital costs of these patients throughout the follow-up.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The nearly 3-fold increase in prevalence of diagnosed MF\/SS during 1998\u20132016 puts pressure on the health care system, as this is a high-cost patient group with a heavy burden of comorbidities. The challenge can be in part answered by shifting the treatment of MF\/SS to a more outpatient-based practice, and by adapting new pharmacotherapy, as has been done in Finland.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12913-021-06109-9","type":"journal-article","created":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T12:04:16Z","timestamp":1613995456000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Mycosis fungoides and S\u00e9zary syndrome: a population-wide study on prevalence and health care use in Finland in 1998\u20132016"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4219-1899","authenticated-orcid":false,"given":"Jaana","family":"Keto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Hahtola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miika","family":"Linna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liisa","family":"V\u00e4kev\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,22]]},"reference":[{"key":"6109_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","volume":"77","author":"F Trautinger","year":"2017","unstructured":"Trautinger F, Eder J, Assaf C, et al. European organisation for research and treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome \u2013 update 2017. Eur J Cancer. 2017;77:57\u201374.","journal-title":"Eur J Cancer"},{"key":"6109_CR2","doi-asserted-by":"publisher","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","volume":"28","author":"NS Agar","year":"2010","unstructured":"Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides\/S\u00e9zary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28:4730\u20139.","journal-title":"J Clin Oncol"},{"key":"6109_CR3","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1001\/jamadermatol.2013.5526","volume":"149","author":"K Korgavkar","year":"2013","unstructured":"Korgavkar K, Xiong M, Weinstock M. Changing incidence trends of cutaneous T-cell lymphoma. JAMA Dermatol. 2013;149:1295\u20139.","journal-title":"JAMA Dermatol"},{"key":"6109_CR4","doi-asserted-by":"publisher","first-page":"735","DOI":"10.2340\/00015555-2629","volume":"97","author":"L V\u00e4kev\u00e4","year":"2017","unstructured":"V\u00e4kev\u00e4 L, Lipsanen T, Sintonen H, et al. Morbidity and causes of death in patients with cutaneous T-cell lymphoma in Finland. Acta Derm Venereol. 2017;97:735\u20138.","journal-title":"Acta Derm Venereol"},{"key":"6109_CR5","doi-asserted-by":"publisher","first-page":"451","DOI":"10.2340\/00015555-1496","volume":"93","author":"E Hodak","year":"2013","unstructured":"Hodak E, Lessin S, Friedland R, et al. New insights into associated co-morbidities in patients with cutaneous T-cell lymphoma (mycosis fungoides). Acta Derm Venereol. 2013;93:451\u20135.","journal-title":"Acta Derm Venereol"},{"key":"6109_CR6","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1080\/09546634.2018.1466026","volume":"29","author":"Y Tsang","year":"2018","unstructured":"Tsang Y, Gu T, Sharma G, et al. Healthcare resource utilization, costs of care, and treatment of mycosis fungoides cutaneous T-cell lymphoma patterns in a large managed care population: a retrospective US claims-based analysis. J Dermatolog Treat. 2018;29:747\u201353.","journal-title":"J Dermatolog Treat"},{"key":"6109_CR7","first-page":"270","volume":"90","author":"E Ricci","year":"2005","unstructured":"Ricci E, Cortelazzo S, Krulichova I, et al. Direct medical costs of mycosis fungoides in specialized Italian hospital departments. Haematologica. 2005;90:270\u20132.","journal-title":"Haematologica"},{"key":"6109_CR8","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1177\/1403494812456637","volume":"40","author":"R Sund","year":"2012","unstructured":"Sund R. Quality of the Finnish hospital discharge register: a systematic review. Scand J Public Health. 2012;40:505\u201315.","journal-title":"Scand J Public Health"},{"key":"6109_CR9","first-page":"179","volume-title":"Evaluating hospital policy and performance: contributions from hospital policy and productivity research. Advances in health economics and health services research","author":"M Linna","year":"2008","unstructured":"Linna M, H\u00e4kkinen U. Benchmarking Finnish Hospitals. In: Blank J, Valdmanis V, editors. Evaluating hospital policy and performance: contributions from hospital policy and productivity research. Advances in health economics and health services research, vol. 18. Oxford: Elsevier; 2008. p. 179\u201390."},{"key":"6109_CR10","volume-title":"Diagnosis-Related Groups in Europe: Moving towards transparency, efficiency and quality in hospitals","author":"M Linna","year":"2011","unstructured":"Linna M, Virtanen M, DRG N. The benefits of coordination. In: Busse R, Geissler A, Quentin W, Wiley M, editors. Diagnosis-Related Groups in Europe: Moving towards transparency, efficiency and quality in hospitals. Maidenhead: Open University Press; 2011."},{"key":"6109_CR11","unstructured":"Kapiainen S, V\u00e4is\u00e4nen A, Haula T. Social and health care unit costs in Finland 2011. Finnish Institute for Health and Welfare 2014 (in Finnish). Available at: http:\/\/urn.fi\/URN:ISBN:978-952-302-079-5 (accessed 26 April 2020)."},{"key":"6109_CR12","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/j.1365-2133.2008.08852.x","volume":"160","author":"M Saunes","year":"2009","unstructured":"Saunes M, Nilsen TI, Johannesen TB. Incidence of primary cutaneous T-cell lymphoma in Norway. Br J Dermatol. 2009;160:376\u20139.","journal-title":"Br J Dermatol"},{"key":"6109_CR13","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2340\/00015555-1359","volume":"92","author":"L V\u00e4kev\u00e4","year":"2012","unstructured":"V\u00e4kev\u00e4 L, Ranki A, Hahtola S. Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland. Acta Derm Venereol. 2012;92:258\u201363.","journal-title":"Acta Derm Venereol"},{"key":"6109_CR14","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1001\/archderm.136.4.504","volume":"136","author":"R van Doorn","year":"2000","unstructured":"van Doorn R, Van Haselen CW, van Voorst Vader PC, et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol. 2000;136:504\u201310.","journal-title":"Arch Dermatol"},{"key":"6109_CR15","volume-title":"Health care costs of men and women by age groups 2011","author":"S Kapiainen","year":"2014","unstructured":"Kapiainen S, Eskelinen J. Health care costs of men and women by age groups 2011. Helsinki: Report 17\/2014 of the Finnish Institute for Health and Welfare (in Finnish); 2014. ISBN 978-952-302-191-4"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-021-06109-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12913-021-06109-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-021-06109-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T12:13:24Z","timestamp":1613996004000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-021-06109-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,22]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6109"],"URL":"https:\/\/doi.org\/10.1186\/s12913-021-06109-9","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,22]]},"assertion":[{"value":"28 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JK was an employee of Kyowa Kirin International at the time when the study was initiated, and she was involved in the design of the study, in the collection, analysis, and interpretation of data, and in writing the manuscript. SH: None. ML: None. LV: None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"166"}}